Daniel Tardiff
Chief Scientific Officer CAMP4 Therapeutics
Dan Tardiff, PhD, is Chief Scientific Officer of CAMP4 where he oversees Platform and Discovery Teams to expand the scope of CAMP4’s discovery platform and advance the pipeline towards the clinic.
Prior to joining CAMP4, Dr. Tardiff led drug discovery projects and teams in both small biotech and large pharma across multiple drug modalities. Dr. Tardiff most recently led a team in the Rare Disease Research Unit at Pfizer exploring genetic medicines for rare neurological disorders. Prior to Pfizer, Dr. Tardiff was a scientific co-founder of Yumanity Therapeutics, where he helped build a platform to discover novel therapeutics for the treatment of neurodegenerative diseases. At Yumanity, he led teams from screening through translational research to discover new therapeutic targets and drug candidates, including a clinical-stage small molecule targeting stearoyl-CoA desaturase for the potential treatment of Parkinson’s disease.
Seminars
- Explore the rationale and approach for targeting non-coding RNAs to upregulate gene expression for diverse therapeutic applications
- Discuss how the platform enables discovery of antisense oligonucleotides that can increase transcription across a range of therapeutic indications and target tissues.
- Provide case studies on the translation and development of candidate ASOs from preclinical research to the clinic
